Monday, 24 June 2002 00:00

New Indication Augments Company's Global Leadership in Light-Based Skin Therapies

ORANGEBURG, N.Y. /PRNewswire:  Radiancy, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted it clearance to market the company's innovative SkinStation(TM) multiple application platform for the treatment of pigmented and vascular lesions, as well as hair removal.

The SkinStation system is the latest advance from Radiancy, featuring the company's proprietary multiple application platform entitled LHE(TM), where light and heat energy are combined to achieve a variety of therapeutic and aesthetic effects with no patient downtime and few, if any, side effects. Outside of the US, the LHE technology already holds a global leadership position with physicians in the effective treatment of numerous skin conditions, including acne, hair removal, psoriasis, pigmented lesions and vascular lesions.

"We're delighted to have received this indication," said Fabian Tenenbaum, Vice President of Marketing and Sales for Radiancy. "Our original intent for the SkinStation was to develop a robust light-based technology that was more compact and less expensive than available alternatives, so it could be used by a greater number of physicians to treat a wide variety of skin conditions. This new indication is yet another step in realizing that vision. It also underscores the versatility of the LHE technology, and as such, represents a major milestone for the company in providing unparalleled safety and efficacy in the treatment of a wide variety of aesthetic conditions."

According to Steven Shapiro, MD, a Dermatologist in private practice in Palm Beach Gardens, Florida, and a primary investigator, "The four qualities of sun damaged conditions are skin redness from blood vessels, pigmented lesions, atrophy or thinning of the skin and hyperpigmentation. The SkinStation system allowed us to treat all four qualities successfully. In pigmented lesions, we basically saw up to a 100% clearance, and in some cases, after only one treatment," added Dr. Shapiro.

Along with this new indication, the SkinStation system is currently under investigational use in more than 30 US clinical sites under the National Acne Research Project (NARP) for the treatment of mild to severe acne vulgaris.

Added Mr. Tenenbaum, "This new indication allows us to highlight the many advantages of the SkinStation system in the treatment of numerous skin conditions, including vascular lesions, telangiectiosis, rosecea, and pigmented lesions like age spots and sun-damaged skin. And the flexibility of our breakthrough LHE technology sets the stage for even greater therapeutic versatility in the future, as the worldwide physician community can already attest."

Founded in 1998 with corporate headquarters in Orangeburg, New York, Radiancy is dedicated to the development of unique medical and aesthetic products that employ its proprietary LHE technology, enabling Light and Heat to work together effectively and efficiently. Using LHE, Radiancy's solutions are more efficient, safer and cost effective.
With corporate offices around the world and sales in more than 40 countries, Radiancy is the global leader in light based skin therapies.